Talis Biomedical Corp (TLIS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues [+]	4.8	8.2	10.9	23.8	18.4
Royalties				23.8	18.4
Revenue growth	-41.3%	-25.1%	-54.1%	29.5%
Cost of goods sold	8.4	0.0	0.0	30.7	23.8
Gross profit	-3.6	8.2	10.9	-6.9	-5.4
Gross margin	-74.4%	100.0%	100.0%	-28.8%	-29.5%
Selling, general and administrative [+]	40.7	42.4	13.1	6.9	5.4
General and administrative				6.9	5.4
Research and development	70.8	157.6	89.0
Other operating expenses				13.0	10.6
EBITDA [+]	-106.3	-190.2	-90.4	-26.0	-20.8
EBITDA growth	-44.1%	110.4%	248.1%	25.0%
EBITDA margin	-2209.2%	-2322.0%	-826.7%	-109.1%	-113.0%
Depreciation and amortization	8.8	1.6	0.8	0.7	0.6
EBIT [+]	-115.1	-191.8	-91.2	-26.7	-21.4
EBIT growth	-40.0%	110.4%	241.5%	24.6%
EBIT margin	-2392.7%	-2341.2%	-833.6%	-112.1%	-116.5%
Interest income				0.0	0.1
Interest income				0.0	0.1
Other income (expense), net [+]	2.1	-0.2	0.1	53.0
Other	2.1	-0.2	0.1
Pre-tax income	-113.0	-192.0	-91.1	26.4	-21.3
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-113.0	-192.0	-91.1	26.4	-21.3
Net margin	-2348.5%	-2343.9%	-833.2%	110.8%	-116.0%

Basic EPS [+]	($4.24)	($8.48)	($42.98)	$34.34	($40.62)
Growth	-49.9%	-80.3%	-225.2%	-184.5%
Diluted EPS [+]	($4.24)	($8.48)	($42.98)	$12.27	($40.62)
Growth	-49.9%	-80.3%	-450.4%	-130.2%

Shares outstanding (basic) [+]	26.6	22.7	2.1	0.8	0.5
Growth	17.6%	968.5%	176.0%	46.3%
Shares outstanding (diluted) [+]	26.6	22.7	2.1	2.2	0.5
Growth	17.6%	968.5%	-1.4%	309.5%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.